CA-AQUA-SPHERE
25.8.2020 11:02:11 CEST | Business Wire | Press release
Aqua Sphere , the premier swimming and triathlon equipment brand, today announced World Champion triathlete Mirinda “Rinny” Carfrae is joining the team as a global brand ambassador. As part of the Aqua Sphere team of athletes, Carfrae will train and compete utilizing the industry-leading Aqua Sphere range of products from training equipment to performance swimsuits and goggles.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200825005255/en/
Carfrae, a three-time Ironman World Champion, will help grow the brand globally alongside her husband and fellow World Champion triathlete, Timothy O’Donnell. Carfrae and O’Donnell are part of Aqua Sphere’s growing roster of elite athletes that also includes World Champion Terenzo Bozzone, among others.
“I’m thrilled to be joining the Aqua Sphere team alongside my husband, Tim. I appreciate the long-term brand vision and I’m confident that Tim and I can make an immediate impact, especially as we embark on product designs heading into 2021,” said Carfrae. “Aqua Sphere has a significant global reach and their wide range of categories fit all our training and racing needs. The goggles fit great and have perfect clarity and I can’t wait to race in the gear once we start competitions again. Everyone we have worked with at Aqua Sphere shares an amazing passion for the brand and has welcomed us like family. And yes, the kid’s goggles are also Izzy approved.”
As a leader in the development of new and innovative swim products for athletes of all ages and abilities, Aqua Sphere has tapped Carfrae to endorse its entire product portfolio, including eye protection, swimwear, triathlon wetsuits and speedsuits, and swim fitness and training accessories. She will also contribute her unique perspective and insight to future product innovations.
“Rinny is a world class athlete who is dedicated to her sport and her family, and we are fortunate to have her join our team at Aqua Sphere,” said Andrew Gritzbaugh, General Manager of Aqua Lung, the parent company of Aqua Sphere. “As one of the world’s most decorated female triathletes, her experience, insights and talent are welcomed assets to the Aqua Sphere brand as we continue to solidify our category leadership position in the triathlon space.”
Originally from Australia, and now residing in Boulder, Colo., Carfrae is one of the world’s most successful triathletes. She has won three Ironman World Championships in 2010, 2013, and 2014 and her run course record from 2014 still stands today (2:50:26). With over 50 wins at major events throughout the world and seven podium performances at Kona in the span of a decade, Carfrae is recognized as one the of the greatest triathletes of all time.
Carfrae is currently gearing up to compete at Ironman World Championships – Kona in 2021.
About AQUA SPHERE
Established in Genoa, Italy, in 1998, Aqua Sphere is the premier swimming and triathlon equipment brand. With the launch of its cutting-edge Seal Mask—the world’s first swim mask, the company set the industry standard and today continues to innovate with a complete range of premium products, including eye protection, swimwear, triathlon wetsuits, speedsuits, swim fitness and training accessories. The designs have gained the respect and loyal following of many celebrities and notable athletes, including the world’s most decorated Olympian Michael Phelps, with whom Aqua Sphere has launched Phelps, a global brand of performance swimwear. Alongside its parent company Aqua Lung and supported by an international distribution network, Aqua Sphere has grown into a worldwide enterprise representing unparalleled design, development and manufacturing expertise, with a global footprint in more than 60 countries. For more information, visit: www.AquaSphereSwim.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20200825005255/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
FDA Issues Modified Risk Tobacco Product Orders for 20 ZYN Nicotine Pouch Products30.6.2026 18:19:00 CEST | Press release
FDA’s decision makes ZYN the first nicotine pouch product to receive MRTP orders authorizing reduced-risk claims versus cigarettes Philip Morris International Inc. (PMI) (NYSE: PM) today announced that the U.S. Food and Drug Administration (FDA) issued Modified Risk Tobacco Product (MRTP) orders for 20 variants of ZYN nicotine pouch products. These are the first MRTP orders granted for nicotine pouches, allowing PMI U.S. to market the following claim for the authorized ZYN products: “Using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.” “FDA’s decision is an important moment for the more than 45 million legal-age nicotine consumers in America,” saidStacey Kennedy, PMI U.S. CEO. “Today’s news ensures these adultshave access to accurate, science-based information, including FDA-authorized evidence that switching from cigarettes to ZYN reduces the risk of smoking-related diseases like heart disease
Caidya Announces Strategic Combination with Simbec-Orion Bridging Early Scientific Insight and Global Clinical Execution30.6.2026 17:00:00 CEST | Press release
Caidya today announced a strategic combination with Simbec-Orion designed to close the divide between early scientific insight and global clinical execution. The combination of Caidya and Simbec-Orion creates a differentiated specialty clinical CRO platform that enables programs to scale, maintaining focus, speed, and accountability. The strategic combination brings together complementary strengths to create a more complete development partner for innovative biopharma companies. With established operations across Europe, the Americas, APAC, and China, the combined organization provides meaningful expertise and execution capabilities in the regions that matter most. Simbec-Orion brings early-phase clinical pharmacology capabilities alongside deep therapeutic expertise for later stage complex oncology and rare disease trials, helping sponsors shape critical decisions early in the development lifecycle. Together, the organizations strengthen their ability to support complex, cross-border
Archer® Proves Purpose-Built AI Beats General-Purpose LLMs on Regulatory Change Management: 95% Verified Accuracy, 80x Faster, 92% Lower Cost30.6.2026 16:13:00 CEST | Press release
In a head-to-head benchmark, a leading general-purpose LLM was confidently wrong 35% of the time on regulatory dates. Archer Evolv™ shipped zero errors. For enterprises deploying AI in compliance, a wrong date is a missed deadline. The more dangerous failure is a wrong answer the model returns with high confidence, one that flows silently into a compliance calendar and is only discovered after the window has passed. Archer® today released results showing purpose-built AI beats a general-purpose large language model (LLM) on regulatory work, and it’s not close. This head-to-head test compared Archer’s purpose-built, vertical-specific AI and proprietary data sets against a leading general-purpose LLM, on a core compliance task: determining the publication, effective and comment-close dates of regulatory documents across six jurisdictions. General-purpose models are a genuine breakthrough, and this is no referendum on their quality. The question Archer set out to answer is narrower and mo
Altasciences Supports Key Development Milestone for Steel Therapeutics’ Lead Therapeutic Candidate, Fizurex™30.6.2026 16:08:00 CEST | Press release
Altasciences, a leading drug development organization, today announced a significant milestone in the development of Steel Therapeutics, Inc.’s pivotal toxicology study for its lead product candidate, Fizurex™, for the treatment of anal fissures. The successful completion of the study plays a significant role in the advancement of Fizurex™ toward first-in-human trials. The GLP-compliant study demonstrated a favorable safety profile, which has advanced Steel Therapeutics' plans to submit an Investigational New Drug (IND) application for Fizurex™ to the FDA in Q3 2026. Fizurex™, a patent-pending, single-use topical wipe, was designed to provide a standardized, accessible treatment option for a painful and often undertreated medical condition. The product builds on years of use through compounding pharmacy prescriptions and is now advancing toward clinical development and regulatory review. "We are proud to have supported Steel Therapeutics with the generation of the high-quality safety d
Interactive Brokers Expands Access to Korean Equities with Launch of Nextrade ATS30.6.2026 16:00:00 CEST | Press release
IB SmartRouting℠ Routes Orders to the Best Available Price Between KRX and Nextrade Interactive Brokers (Nasdaq: IBKR), an automated global broker, today announced the launch of select Korean equities through Nextrade, South Korea's first Alternative Trading System (ATS). The addition of Nextrade builds on Interactive Brokers' earlier launch of the Korea Exchange (KRX), through which it became the first major US-based broker to provide global investors with direct access to Korean equities. Clients trading on Nextrade benefit from significantly extended trading hours and access to additional liquidity. Interactive Brokers has enabled IB SmartRouting℠ across both the Korea Exchange (KRX) and Nextrade, automatically routing orders to the venue offering the best price. This helps clients achieve best execution while providing greater flexibility and more opportunities to participate in one of Asia's most dynamic equity markets. Korea's equity market ranks among the top global exchanges by
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom